News | March 13, 2013

CircuLite Receives Conditional IDE Approval for Synergy Feasibility Trial

March 13, 2013 — CircuLite Inc. announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for an investigational device exemption (IDE) for its lead product, the Synergy circulatory support system, a minimally invasive device designed to reverse the symptoms of heart failure in ambulatory chronic heart failure patients.

Heart failure is a progressive disease. Once patients deteriorate to the point of experiencing persistent, severe symptoms despite receiving optimal medical treatment (ACE inhibitor, beta blocker, defibrillator and/or pacemaker), their options are very limited. Synergy is the world’s smallest circulatory support pump — approximately the size and weight of a AA battery — and is designed to work in synergy with the native heart to improve blood flow to the brain and body, rather than replace the heart’s function. The procedure is minimally invasive and does not require open-heart surgery, eliminating the need for cardiopulmonary bypass. In a European CE mark clinical study, Synergy was shown to improve hemodynamics, exercise capacity and overall quality of life in ambulatory chronic heart failure patients (INTERMACS ?4 or NYHA Class III/IV).

“Many ambulatory chronic heart failure patients have a very poor quality of life today,” said Daniel Burkhoff, M.D., Ph.D., chief medical officer of CircuLite and adjunct associate professor of medicine at Columbia University Medical School. “Despite running the gamut of heart failure treatment, they are severely restricted by their symptoms, yet are not sick enough to justify more invasive surgical treatment options. Synergy has the potential to reverse many of the abnormalities that underlie those symptoms, with the goal of improving a patient’s activity level and quality of life.”

With receipt of conditional IDE approval, CircuLite plans to commence its U.S. clinical trial evaluating the use of the system for long-term support in ambulatory chronic heart failure patients (INTERMACS ?4) who remain symptomatic despite optimal medical management. The IMPACT (Safety EvaluatIon of the CircuLite SYNERGY Circulatory Assist Device in a Non-Inotrope Dependent, AMbulatory Patient with End-StAge Chronic Heart Failure: A PiloT Study) trial is a 20-patient feasibility trial that will be conducted at seven U.S. clinical sites.

“Beginning our U.S. feasibility trial marks a significant milestone for the company, and is the first step on our path to providing a new treatment option to tens of thousands of U.S. ambulatory chronic heart failure patients who have no other options today,” said Paul Southworth, CEO of CircuLite.

The minimally invasive Synergy procedure is performed through a mini-thoracotomy, and the micro-pump is implanted in a shallow “pacemaker pocket.” It requires no bypass and enables a quick recovery, offering the potential to impact the economics of treating ambulatory chronic heart failure patients.

Synergy received CE mark in September 2012 and is currently conducting a controlled commercial rollout in Europe.

The Synergy circulatory support system is a micro-blood pump that provides up to 4.25 liters of blood per minute and reduces the heart's workload while improving blood flow to vital organs. In addition, it is intended to reduce re-hospitalizations associated with heart failure symptoms. Synergy is designed and manufactured in Aachen, Germany.

For more information: www.circulite.net

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Overlay Init